The growth of the North American Nuclear Medicine market can be mainly attributed to factors such as increasing incidence and prevalence of cancer and heart disease and initiatives to close the supply-demand gap for Mo-99.
[159 Pages Report] The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108
Report Scope and Market Segmentation:
|
Report Metric |
Details |
|
Market Size Available for Years |
2019–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2022–2026 |
|
Forecast Units |
Value (USD Billion) |
|
Segments Covered |
Type, Application, Procedural Volume, And Country |
|
Geographies Covered |
North America (US & Canada) |
|
Companies Covered |
The major 20 players of the market include Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), JSC Isotope (Russia), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Jubilant DraxImage (Canada), PharmaLogic (US), Institute of Isotopes Co., Ltd. (Hungary), Sinotau Pharmaceuticals (China), Isotopia Molecular Imaging Limited (Israel), SHINE Medical Technologies (US), and Global Medical Solutions (US). |
By type, the SPECT radiopharmaceutical segment is expected to account for the largest share of the diagnostic nuclear medicine market
Based on type, the North American nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The diagnostic nuclear medicine segment is further categorized into SPECT and PET radiopharmaceuticals. The SPECT radiopharmaceuticals segment is expected to account for the largest share of the market
By application, the PET oncology application segment is expected to account for the largest share of the market
Based on application, the North American nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The PET applications segment is further segmented into oncology, cardiology, and neurology, among others. The oncology PET application segment is projected to register the highest growth rate in the forecast period.
The US to dominate the market
The North American nuclear medicine market is segmented into the US and Canada, based on country. The US is expected to account for the largest share and also register the highest CAGR during the forecast period. The growth of this market can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country
Cardinal Health (US) is one of the major players in the North American nuclear medicine market. Cardinal Health is a healthcare services company providing pharmaceutical and medical products & services to healthcare providers. Cardinal Health operates in the US, Canada, the British Virgin Islands, Malaysia, Singapore, the UK, Luxembourg, Thailand, Switzerland, Ireland, and Belgium through its 150 subsidiaries.
Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108
